PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, alone or with standard chemotherapy, in people with metastatic pancreatic cancer that has spread. About 900 adults with a RAS gene mutation will be randomly assigned to one of three treatment groups. The goal is to see if the new d…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 10:11 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a powerful chemotherapy directly to cancer cells. The goal is to see if it can shr…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated May 17, 2026 10:07 UTC
-
New drug STRO-004 enters human trials for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called STRO-004 in about 200 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in m…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 10:06 UTC
-
New combo aims to improve pancreatic cancer surgery outcomes
Disease control Recruiting nowThis early-phase trial tests whether adding fostamatinib (a drug already approved for a blood disorder) to standard chemotherapy can help people with resectable pancreatic cancer. About 36 adults will receive the combination before and after surgery. The main goal is to see if th…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug targets tough pancreatic cancer mutation in 60-Patient trial
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow cancer growth, and to check for side effects. Participants must have a confi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage study tests a new drug called KO-2806 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors, either alone or combined with other therapies. About 300 adults wi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New cocktail targets Stomach-Lining pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard vein chemotherapy (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will rece…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for advanced cancers: experimental drug BMS-986523 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called BMS-986523, either alone or with other cancer medicines, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change (KRAS). The main goals are to see if the drug is safe and to fin…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has worsened after one prior treatment. The drug targets a specific protein on cancer cells. The goal is to see if it can shrink tumors and to check for side effects. All 39 parti…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for pancreatic cancer? early trial combines targeted drug with chemo
Disease control Recruiting nowThis early-phase trial tests a new drug called ProAgio alongside standard chemotherapy (gemcitabine and nab-paclitaxel) with or without an immunotherapy drug (atezolizumab) in people with advanced pancreatic cancer that has spread. The main goals are to find a safe dose and see h…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy targets tough pancreatic cancer
Disease control Recruiting nowThis study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New cell therapy targets Hard-to-Treat cancers using Biopsy-Guided strategy
Disease control Recruiting nowThis study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug JYP0015 targets RAS-Mutant cancers in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New radiation therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new treatment that delivers radiation directly to cancer cells in people with advanced solid tumors that cannot be removed by surgery. The treatment uses a special molecule to find and attach to cancer cells, then delivers a radioactive payload to destroy …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Engineered immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment made from a person's own immune cells (NK cells) that are engineered to recognize and attack pancreatic cancer cells. The study includes 42 adults with advanced pancreatic cancer that has spread or cannot be removed by surgery. The goa…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Can your Tumor's DNA predict chemo success? new study aims to find out
Disease control Recruiting nowThis study looks at how the genetic makeup of pancreatic cancer affects response to FOLFIRINOX chemotherapy given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive chemo, then have their tumors analyzed. The goal is to see if certain tumor types r…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:57 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors that have specific RAS gene mutations, including certain lung, colorectal, and pancreatic cancers. The main goals are to check the drug's safety and find the right dose. Participa…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
New hope for pancreatic cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called BNT327 combined with chemotherapy in people with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination can shrink tumors and control the disease. About 105 adults will take part, and the study is cu…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Radioactive implant fights pancreatic cancer from the inside
Disease control Recruiting nowThis early study tests a new treatment for pancreatic cancer that cannot be removed by surgery. Ten participants will receive a single injection of a radioactive implant directly into their tumor, along with standard chemotherapy. The goal is to see if the combination is safe and…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: BetaGlue Therapeutics SpA • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
New drug duo tested in fight against tough pancreatic cancer
Disease control Recruiting nowThis early-stage study is testing the safety and effectiveness of a new drug combination (HRS-4642 plus nimotuzumab) for people with advanced pancreatic cancer that has returned or spread. The study will enroll about 20 patients to find the right dose and see if the treatment can…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New scan could sharply improve pancreatic cancer staging
Diagnosis Recruiting nowThis study tests a new type of PET/CT scan (called [¹⁸F]FAPI-74) to see if it can more accurately detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the scan tracer and be followed for up to 3 m…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: SOFIE • Aim: Diagnosis
Last updated May 17, 2026 10:11 UTC
-
New scan could spot pancreatic cancer sooner
Diagnosis Recruiting nowThis study is testing a new type of PET scan called FAPI PET to see if it can find pancreatic cancer progression or return earlier than current tests like CT or MRI. About 35 adults with pancreatic cancer that hasn't spread will get FAPI scans at several points during their treat…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Diagnosis
Last updated May 15, 2026 11:57 UTC
-
New blood test could spot several gut cancers before symptoms start
Diagnosis Recruiting nowThis study aims to create a blood test that can detect several types of gastrointestinal cancers—like liver, pancreatic, and colon cancer—at an early stage. Current screening methods are often invasive or not sensitive enough. The test looks for tiny molecules called miRNAs in th…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated May 12, 2026 13:40 UTC
-
Scientists hunt for clues to beat liver metastases in colorectal and pancreatic cancers
Knowledge-focused Recruiting nowThis study is gathering detailed information from 625 people with colorectal or pancreatic cancer that has spread to the liver, as well as from healthy volunteers. Researchers will analyze tumor and blood samples to understand how the immune system interacts with these cancers. T…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 17, 2026 10:07 UTC